Tag: liver diseases therapeutics market segments

  • Global Liver Diseases Therapeutics Industry Trends and Market Forecast 2026–2030

    Global Liver Diseases Therapeutics Industry Trends and Market Forecast 2026–2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the liver diseases therapeutics market from 2026–2035 with trusted insights from The Business Research Company

    What market expansion outlook does the Liver Diseases Therapeutics Market show for the 2026–2030 period?

    The liver diseases therapeutics market has experienced substantial growth in recent years. Projections indicate it will expand from $15.18 billion in 2025 to $16.66 billion in 2026, at a compound annual growth rate (CAGR) of 9.8%. This historical growth can be attributed to several factors, including the high prevalence of viral hepatitis infections, an increase in alcohol-induced liver disease cases, early reliance on antiviral and supportive therapies, the limited treatment options available for chronic liver conditions, and the expansion of hospital-based liver care.

    The liver diseases therapeutics market size is projected to experience substantial expansion in the coming years. This market is forecast to reach $24.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.9%. This anticipated growth during the forecast period is fueled by factors such as the increasing prevalence of metabolic liver diseases, the greater uptake of immunosuppressive and targeted therapeutic approaches, the expansion of treatment pipelines for liver cancer, a heightened understanding of the advantages of early intervention, and elevated healthcare expenditure on chronic liver conditions. Key trends emerging over the forecast horizon encompass a surge in demand for antiviral treatments for hepatitis, a sharpened focus on managing NAFLD and NASH, the increasing integration of immunotherapy in liver cancer treatment, the broadening scope of combination drug therapies, and a heightened priority placed on enduring disease management strategies.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

    What Drivers Are Shaping The Development Of The Liver Diseases Therapeutics Market?

    The increasing occurrence of liver conditions is anticipated to fuel the expansion of the liver disease therapeutics market in the future. Liver disease encompasses any ailment impacting the liver, and therapeutics for liver diseases aid in managing these conditions through diverse treatment approaches. As an illustration, the Office for Health Improvement and Disparities, a UK-based government department, stated in December 2024 that premature deaths attributed to alcoholic liver disease saw a 3.6% rise in 2023, totaling 5,984, an increase from 5,776 in 2022. Consequently, the growing incidence of liver diseases is a primary driver for the expansion of the liver disease therapeutics market.

    What Segment Types Are Examined In The Liver Diseases Therapeutics Market?

    The liver diseases therapeutics market covered in this report is segmented –

    1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

    2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

    3) By End User: Hospitals, Ambulatory Surgery Centers

    Subsegments:

    1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

    2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

    3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

    4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

    How Are New Market Trends Shaping The Landscape Of The Liver Diseases Therapeutics Market?

    Leading firms within the liver disease therapeutics market are concentrating on pioneering technologies, specifically artificial intelligence, to facilitate early detection of liver fibrosis in patients by clinicians during their disease advancement. The implementation of artificial intelligence in liver disease therapeutics involves utilizing sophisticated computational algorithms and machine learning approaches to process medical data, thereby assisting in prompt identification, accurate diagnosis, and tailored treatment plans for various liver conditions. An example of this is Predictive Health Intelligence, a UK-based healthcare information management enterprise, which introduced hepatoSIGHT in February 2023. This innovative AI-driven tool is capable of predicting liver fibrosis in individuals suffering from chronic liver disease. It functions as a case-finding and cohort mapping utility, specifically engineered to pinpoint patients susceptible to chronic liver disease (CLD). The system is secure, user-friendly, and intuitive, possessing the ability to rapidly scan millions of data lines in mere seconds to pinpoint patients who fulfill particular criteria. Furthermore, its capabilities encompass thorough data analysis, the application of machine learning algorithms, real-time risk assessment, and a straightforward interface.

    Who Are The Top-Performing Companies In The Liver Diseases Therapeutics Market In Recent Years?

    Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

    How Does The Liver Diseases Therapeutics Market Perform Across Major Global Regions?

    North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Liver Diseases Therapeutics Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

    Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

    Fatty Liver Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

    Hepatitis Therapeutics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

    Liver Health Supplements Market Report 2026

    https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Liver Diseases Therapeutics Market Revenue and CAGR Forecast Analysis 2025–2029

    Global Liver Diseases Therapeutics Market Revenue and CAGR Forecast Analysis 2025–2029

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Is The Current Size And Growth Outlook For The Liver Diseases Therapeutics Market?

    The therapeutics market for liver diseases has seen a robust growth over the past few years. The market value is expected to rise from $14.16 billion in 2024 to $15.18 billion in 2025, with a 7.2% Compound annual growth rate (CAGR). The historic expansion of this market is linked to the high frequency of liver disorders, habits of alcohol consumption, improvements in diagnostic technologies, obesity and metabolic syndrome issues, awareness and screening initiatives, as well as government-led hepatitis control programs.

    There is an anticipated strong surge in the liver diseases therapeutics market in the coming years. The market is projected to expand to $22.08 billion in 2029, with a compound annual growth rate (CAGR) of 9.8%. The forecasted growth can be linked to precision medicine methods, breakthroughs in RNA therapeutics, emphasis on fibrosis treatments, patient advocacy and support groups, the progression of vaccines for hepatitis, and regulatory backing for orphan drugs. The predicted trend within this period includes progress in hepatitis C treatment, the rise of innovative therapies for liver fibrosis, incorporation of immunotherapies, the use of telemedicine and remote monitoring, and concentration on nutritional interventions.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

    What Core Drivers Are Expected To Influence The Liver Diseases Therapeutics Market?

    The escalating occurrence of liver conditions is anticipated to boost the liver disease therapeutics market’s expansion in the future. The term “liver disease” applies to any ailment that impacts the liver. Liver disease treatments assist in managing these conditions through a variety of therapies. For example, the UK government’s Office for Health Improvement and Disparities stated in April 2024 that as of 2022, the mortality rate owing to liver disease in individuals under the age of 75 in England increased to 21.4 per 100,000 population. Men were found to experience 6,664 premature deaths while women accounted for 3,929. Consequently, the surging incidence of liver diseases is propelling the growth of the liver disease therapeutics market.

    Which Segmentation Categories Are Highlighted In The Liver Diseases Therapeutics Market Analysis?

    The liver diseases therapeuticsmarket covered in this report is segmented –

    1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer

    2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids

    3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users

    Subsegments:

    1) By Hepatitis: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D

    2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH); Simple Fatty Liver

    3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis; Alcoholic Cirrhosis

    4) By Liver Cancer: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma

    Which Trends Are Likely To Redefine Growth Paths In The Liver Diseases Therapeutics Market?

    The prevalence of strategic partnerships is a rising trend in the liver disease therapeutics market. Dominant firms are participating in partnerships to consolidate their standing in this market. For example, in January 2022, Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company based in the United States, joined forces with Merck & Co, another American company active in the liver disease therapeutics sector. The purpose of their collaboration is to research and develop oligonucleotide treatments for non-alcoholic steatohepatitis.

    Who Are The Dominant Players In The Liver Diseases Therapeutics Market Today?

    Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

    Which Regional Markets Are Emerging As Key Hubs For The Liver Diseases Therapeutics Market?

    North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

    Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2025, By The Business Research Company

    Digital Therapeutics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

    Antisense And Rnai Therapeutics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    Transplant Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Liver Diseases Therapeutics Industry Forecast to Hit $22.08 Billion by 2029 With a Strong 9.8% CAGR

    Liver Diseases Therapeutics Industry Forecast to Hit $22.08 Billion by 2029 With a Strong 9.8% CAGR

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Are The Growth Projections For The Liver Diseases Therapeutics Market Size During 2025–2029?

    The liver diseases therapeutics market size has experienced strong growth in recent years. It is projected to expand from $14.16 billion in 2024 to $15.18 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.2%. The historical increase in this market can be attributed to the high prevalence of liver diseases, patterns of alcohol consumption, advancements in diagnostics, the rise of obesity and metabolic syndrome, the implementation of awareness and screening programs, and government initiatives for hepatitis control.

    The liver diseases therapeutics market size is anticipated to undergo robust expansion in the coming years. This market is expected to reach $22.08 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.8%. The projected growth during this period can be ascribed to factors like precision medicine approaches, innovations in RNA therapeutics, a concentrated focus on fibrosis treatments, the influence of patient advocacy and support groups, the development of vaccines for hepatitis, and regulatory support for orphan drugs. Key trends foreseen in the forecast period include advancements in the treatment of hepatitis C, the emergence of novel therapies for liver fibrosis, the exploration of immunotherapies, the adoption of telemedicine and remote monitoring, and an increased emphasis on nutritional interventions.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

    What Are The Emerging Market Drivers Creating New Opportunities In The Liver Diseases Therapeutics Industry?

    The escalating occurrence of liver diseases is anticipated to propel the expansion of the liver disease therapeutics market in the foreseeable future. Liver disease refers to any condition that affects the liver, and liver disease therapeutics are designed to help treat these conditions through various methods. For instance, in April 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, data from 2022 showed that the mortality rate from liver disease among individuals under 75 years old in England rose to 21.4 per 100,000 population. During this period, males experienced 6,664 premature deaths, compared to 3,929 for females. Consequently, the rising prevalence of liver diseases is a key factor driving the growth of the liver disease therapeutics market.

    Which Key Segments Fueling The Liver Diseases Therapeutics Market?

    The liver diseases therapeuticsmarket covered in this report is segmented –

    1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer

    2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids

    3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users

    Subsegments:

    1) By Hepatitis: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D

    2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH); Simple Fatty Liver

    3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis; Alcoholic Cirrhosis

    4) By Liver Cancer: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma

    Which Market Trends Are Creating New Opportunities In The Liver Diseases Therapeutics Industry?

    Strategic partnerships are a prominent trend gaining traction in the liver disease therapeutics market. Key companies active in the liver diseases therapeutics market are engaging in collaborations to bolster their presence within the sector. For example, in January 2022, Aligos Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, teamed up with Merck & Co, a US-based company involved in liver disease therapeutics. This partnership aims to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis.

    Which Global Market Leaders Are Shaping The Future Of The Liver Diseases Therapeutics Sector?

    Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

    How Is Liver Diseases Therapeutics Market Demand Varying Across Different Regions?

    North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Liver Diseases Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

    Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2025, By The Business Research Company

    Digital Therapeutics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

    Antisense And Rnai Therapeutics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

    Transplant Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model